Cropped view of senior man playing with puzzles

Curriculum

1.75 CME Credit

Managing Agitation in Alzheimer’s Dementia: Current and Future Approaches

Agitation is among the most common behavioral symptoms among patients with dementia, including Alzheimer’s dementia. Agitation in Alzheimer’s dementia (AAD) exacts a significant burden on patients, caregivers, and the health care system because it is associated with not only greater morbidity and mortality, but also a faster cognitive and functional decline. AAD is a leading predictor of which individuals with dementia will be transferred to residential care. It places a high burden on caregivers—leading to reduced quality of life, depression, lower productivity—and higher indirect costs. Pri-Med is offering a multicomponent curriculum on AAD, composed of activities that cover a range of topics, from epidemiology, etiology, clinical presentation, and diagnosis to nonpharmacological and pharmacological treatments and guideline recommendations. We hope you take advantage of these activities and come back often as we will continue to add new activities throughout 2023 and beyond. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on November 30, 2022 and they are subject to change as new information is published.

Begin

CME Information

1.75 AMA PRA Category 1 Credits™, 1.75 ABIM MOC or 1.65 AANP, including 0.81 AANP Pharm

Release Date: 1/20/2023

Available for credit until 7/14/2024

Learning Objectives

  • Discuss the epidemiology of agitation associated with dementia due to Alzheimer’s disease and its burden on patients, caregivers, and the healthcare system
  • Recognize causes and clinical presentation of agitation associated with dementia due to Alzheimer’s disease
  • Identify recommended nonpharmacological interventions for agitation associated with dementia due to Alzheimer’s disease
  • Review the efficacy and tolerability of currently available pharmacotherapies for agitation associated with dementia due to Alzheimer’s disease
  • Discuss the mechanism of action and available efficacy and safety data for emerging therapies for agitation associated with dementia due to Alzheimer’s disease
 

Courses

1.25 CME/CE CREDITS

5 Courses

Faculty Disclosures

Pierre N. Tariot, MD

Director
Banner Alzheimer’s Institute
Co-Director
Alzheimer’s Prevention Initiative
Research Professor of Psychiatry
University of Arizona College of Medicine
Phoenix, Arizona

Learn More
Dr. Joshi Headshot

Pallavi Joshi, DO, MA

Geriatric Psychiatrist
Banner Alzheimer’s Institute 
Clinical Assistant Professor of Psychiatry
Associate Program Director, Geriatric Psychiatry Fellowship
University of Arizona College of Medicine
Phoenix, Arizona

Learn More

Supporters and Partners

Commercial Supporter

Otsuka America Pharmaceutical, Inc. and Lundbeck

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs. 

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. Pri-Med Institute and Vindico Medical Education staff have no relevant financial relationships to disclose.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Managing Agitation in Alzheimer’s Dementia: Current and Future Approaches

Begin